TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03566394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg
Description: Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
Study: NCT01104506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Study: NCT00006253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse
Description: Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-nurse coach
Description: Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
Study: NCT02245269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maalox
Description: Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
Study: NCT03859440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSiHy Silicone hydrogel soft contact lens
Description: •Device: DSiHy (test lens) Silicone hydrogel soft contact lens for daily disposable wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CE-marked Silicone hydrogel soft contact lens
Description: ・Device: Silicone hydrogel soft contact lens CE-marked for daily disposable wear.~Other Name : MyDay
Study: NCT02642393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inosine
Description: capsules containing 500 mg of inosine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules containing \~500 mg of lactose and appearing indistinguishable from inosine capsules
Study: NCT01112774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Stimulation will be applied at 2 mA for a total of 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Stimulation will be applied at 2 mA for a total of 20 minutes.
Study: NCT01588340

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI (Magnetic resonance imaging)
Description: Subject will complete a 15 minute scan in the MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound exam
Description: The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
Study: NCT04643873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity counseiling +pilates exercise group
Description: It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
Study: NCT02662660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Port-sites infiltration:Bupivacaine0.25%
Description: Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural analgesia:Levobupivacaine0,125%
Description: Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
Study: NCT01104506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mTMS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mTMS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mTMS
Study: NCT04643873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity counseiling group
Description: During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
Study: NCT03098550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT04054479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penehyclidine
Description: Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
Study: NCT04310436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modifying saccades by looking down to naval.
Description: Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Modifying saccades by looking in air.
Description: Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
Study: NCT04291196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-ECT 360o Video
Description: Patients in the VR arm will be immersed in the ECT process in first person utilizing Google Cardboard headsets. Patients will experience in 360 entering the procedure room, IV insertion, pretreatment checks, anesthetic induction followed by induction of seizure, and recovery. The experience will also have voice-over narration simultaneously describing the procedure and its risks and benefits.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Treatment
Description: Patients will receive preparation for their ECT as per standard of care, i.e. a discussion with a Psychiatrist.
Study: NCT04516070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study: NCT04424823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LED photobiomodulation
Description: Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: LED photobiomodulation
Description: Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
Study: NCT01935323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Training
Study: NCT01513187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib + interferon alpha 2A
Description: Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient
Study: NCT00245050

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pyridoxine hydrochloride
Description: Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: doxorubicin HCL liposome
Description: IV, 40mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin HCL liposome
Description: IV, 40mg/m2
Study: NCT03443479

Intervention type: DEVICE
Intervention: Non-Invasive Ventilation
Description: Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.

Intervention type: DEVICE
Intervention: High-Flow Nasal Cannula
Description: Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher\&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
Study: NCT02662660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole and Acetaminophen iv
Description: Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole and Acetaminophen iv
Description: Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole and Acetaminophen iv
Description: Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
Study: NCT01602718

Intervention type: OTHER
Group type: OTHER
Intervention: exercise training
Description: Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
Study: NCT01909063

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D, Vitamin E, and Vitamin A
Description: Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control, 700 mg Calcium
Description: Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
Study: NCT03745716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 + azacitidine
Description: Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine
Study: NCT04590638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tumescent with adrenaline
Description: skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tumescent without adrenaline
Description: skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.
Study: NCT04637932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Dilatation Tracheostomy
Description: pro-seal laryngeal mask or intubation tube in bronchoscopy-guided percutaneous dilation tracheostomy procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Dilatation Tracheostomy
Description: pro-seal laryngeal mask or intubation tube in bronchoscopy-guided percutaneous dilation tracheostomy procedure.
Study: NCT00339092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Directly Observed Therapy
Description: Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
Study: NCT03880786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pudendal PNE test lead
Description: All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
Study: NCT01152619

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous repeated dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous repeated dose
Study: NCT02526576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
Study: NCT00683800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate (DVS) SR
Description: Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
Study: NCT03071354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB protein supplement (3g)
Description: HMB 3g/day or iso-nitrogenous control (discussed below) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward. The dose of HMB was chosen based on multiple studies revealing efficacy of 3g/day improving muscle mass and demonstrating an excellent safety profile. Feeding will be initiated as per local practice. Enrolled patients will be randomized to supplementation with HMB (3g) or control will begin within 72 hours of admission to ICU.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Supplement
Description: Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward throughout the study. While the patient is intubated, the control nutritional supplement will be delivered via the enteral feeding tube. The participant will switch to oral administration once extubated
Study: NCT05911451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous fistula creation
Description: It is recommended to create the arteriovenous fistula 3 to 6 months before the expected start of hemodialysis treatment using locoregional anesthesia. It is recommended to use minimal venous and arterial diameters of 2mm for radiocephalic fistulas and 3mm for brachiocephalic and brachiobasilic fistulas. It is recommended to avoid creating an arteriovenous fistula at the same side as a pacemaker, central venous catheter, or arterial stenosis. It is recommended to use the following order of preference for arteriovenous fistula creation: radiocephalic fistula as first choice, brachiocephalic fistula as second choice, and brachiobasilic fistula as third choice.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous graft placement
Description: It is recommended to implant the arteriovenous graft 2 weeks before the expected start of hemodialysis treatment under antibiotic prophylaxis. Implantation of an early-cannulation graft is recommended for patients who require more urgent start of hemodialysis to avoid the use of a temporary central venous catheter. It is recommended to use minimal arterial and venous diameters of 3mm and 4mm, respectively. It is recommended to avoid placing an arteriovenous graft at the same side as a pacemaker, central venous catheter, or arterial stenosis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheter placement
Description: It is recommended to place a tunneled central venous catheter just before the start of hemodialysis treatment under local anesthesia, with conscious sedation if preferred by the patient. The catheter should preferably be placed in the right internal jugular vein with ultrasound-guided puncture and fluoroscopy control under sterile conditions. According to usual practice at the trial center, catheters may be implanted by surgeons, interventional radiologists, or nephrologists.
Study: NCT01500200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Two active tablets, given daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets, given daily
Study: NCT03502369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Quadratus lamborum block
Description: Local anaesthetic will be injected in the fascial plane between psoas major muscle and quadratus lumborum muscle.
Study: NCT00621673

Intervention type: DRUG
Group type: OTHER
Intervention: Kogenate (BAY 14-2222)
Description: Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
Study: NCT03098550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days
Study: NCT01740193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal/iliohypogastric blockade
Description: Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
Study: NCT02310568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865.
Description: Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865.
Description: Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06372865.
Description: Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865.
Description: Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865.
Description: Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
Study: NCT02966028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNF472
Description: Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNF472
Description: Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.